Praetorian Bio, a preclinical biotech company developing the first vaccines directly targeting the bacteria behind cavities and gum disease, is proud to announce its participation in Dentech 2025, where the company has been invited to deliver a Flash Talk .
Dentech is one of the world’s leading events for dental innovation, bringing together researchers, clinicians, industry leaders, and investors. Presenting at Dentech marks an important milestone, providing Praetorian Bio the opportunity to share its vision for prevention-focused oral health with the community that matters most — from academic pioneers and key opinion leaders to potential partners and investors.
“Our vaccine programs are designed to tackle the two most common oral diseases worldwide, using needle-free mucosal delivery to move dentistry from reactive treatments to proactive protection,” said Dr. Ivo Ploemen, Co-CEO of the Company. “Dentech is not just a stage to showcase science — it’s a platform to connect with the ecosystem that can help us turn innovation into impact.”
For Praetorian Bio, presenting at Dentech underscores its ambition to be a leading player in the future of oral health, building momentum toward the clinic and ultimately making vaccines a new reality in dentistry.
